Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.
Create a free account to read 3 full reports each month — plus a 14-day Pro trial. Get started →
HCA Healthcare
HCAHealthcareGenerated Jul 5, 2026, 08:09 PM UTC
HCA (HCA Healthcare) analytical snapshot. Revenue grew +7.9% YoY to $64.97B. Net margin at 8.07% (expanding ▲). Return on equity -209.76%, ROA 9.33%, ROIC 0.00%. Market cap $91.07B at $410.50 per share. Trailing P/E 21.64, P/S 1.40. FCF DCF intrinsic value ≈ $335.49 → implied downside +18.3%. Risk: Elevated. Macro: Risk-on · Supportive. Composite analytical score -14 (data confidence 82%). Descriptive analytics from public filings — not investment advice.
Market cap
$91.07B
221.84M shares
Price
$410.50
NYQ
P/E (ttm)
21.64
Revenue (FY)
$64.97B
YoY +7.9%
Net margin
8.07%
▲ 0.78pp
Free cash flow
$4.69B
7.21% margin
Risk level
Elevated
Free SEC analysis
— computed from SEC filings, free to readFree previewFundamentals Analyst
Fundamentals
Fundamentals Analyst
score 0Stable
80% conf
Revenue grew +7.9% YoY to $64.97B. Net margin at 8.07% (expanding ▲). Return on equity -209.76%, ROA 9.33%, ROIC 0.00%.
- Revenue grew +7.9% YoY to $64.97B.
- Net margin at 8.07% (expanding ▲).
- Return on equity -209.76%, ROA 9.33%, ROIC 0.00%.
- Gross margin 0.00%, operating margin 0.00%.
- Free cash flow margin 7.21% ($4.69B).
- Net income down ▼ +7.1% YoY.
- Debt/equity -7.04, current ratio 0.83, net debt $43.43B.
- Asset turnover 1.06 — capital efficiency.
Revenue (FY)
$64.97B
YoY +7.9%
Net margin
8.07%
▲ 0.78pp
ROE
-209.76%
ROA 9.33%
ROIC
0.00%
EPS (diluted)
$18.97
FY2025
Free cash flow
$4.69B
7.21% margin
Debt / equity
-7.04
Cash $940.0M
Current ratio
0.83
Equity -$6.30B
Annual fundamentals — up to 10 years (SEC 10-K, US-GAAP)
| FY | Revenue | Rev YoY | Gross% | Op% | Net% | FCF | ROE% |
|---|---|---|---|---|---|---|---|
| 2016 | — | — | — | — | — | — | -24.67 |
| 2017 | — | — | — | — | — | — | -29.16 |
| 2018 | — | — | — | — | — | $2.89B | -42.46 |
| 2019 | — | — | — | — | — | $2.41B | -44.77 |
| 2020 | — | — | — | — | — | $3.19B | -134.86 |
| 2021 | $51.34B | — | 0.00 | 0.00 | 6.83 | $3.44B | 612.76 |
| 2022 | $51.53B | +0.4% | 0.00 | 0.00 | 7.28 | $6.40B | -402.36 |
| 2023 | $58.75B | +14.0% | 0.00 | 0.00 | 11.84 | $5.38B | -251.39 |
| 2024 | $60.23B | +2.5% | 0.00 | 0.00 | 9.37 | $4.13B | -318.09 |
| 2025 | $64.97B | +7.9% | 0.00 | 0.00 | 8.07 | $4.69B | -209.76 |
Quarterly revenue trend (last 6 quarters, SEC 10-Q)
| Quarter end | Revenue | YoY | QoQ | Net margin |
|---|---|---|---|---|
| Mar 31, 2025 | $18.32B | +5.7% | — | 8.79% |
| Jun 30, 2025 | $36.93B | +6.0% | +101.6% | 8.84% |
| Jun 30, 2025 | $18.61B | -46.6% | -49.6% | 17.54% |
| Sep 30, 2025 | $56.09B | +7.2% | +201.5% | 8.75% |
| Sep 30, 2025 | $19.16B | -63.4% | -65.8% | 25.60% |
| Mar 31, 2026 | $19.11B | +4.3% | -0.3% | 8.48% |
Revenue (annual, SEC 10-K)
2016: 0
2017: 0
2018: 0
2019: 0
2020: 0
2021: 51,336
2022: 51,533
2023: 58,752
2024: 60,233
2025: 64,968
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Profitability trends (%)
GrossOperatingNet
Free cash flow (annual)
2016: 0
2017: 0
2018: 2,893
2019: 2,411
2020: 3,188
2021: 3,444
2022: 6,397
2023: 5,382
2024: 4,127
2025: 4,687
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sources:SEC EDGAR — Company Facts (XBRL)
Free previewRegulatory Analyst
Filings & Ownership
Regulatory Analyst
score 20Improving
80% conf
Latest annual report (10-K) filed Feb 10, 2026. Latest quarterly report (10-Q) filed Apr 29, 2026. 19 recent 8-K material-event filings in the index.
- Latest annual report (10-K) filed Feb 10, 2026.
- Latest quarterly report (10-Q) filed Apr 29, 2026.
- 19 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 0 sell transactions.
- ~10,000+ recent 13F-HR filings reference HCA Healthcare; broad institutional reporting.
- Recent filers include DSC Advisors, L.P., HOMANS PETER, BRANT POINT INVESTMENT MANAGEMENT LLC.
- 20 recent 13G passive institutional ownership notices.
Latest 10-K
Feb 10, 2026
Annual report
Latest 10-Q
Apr 29, 2026
8-K (recent)
19
Insider net
—
0B/0S
13F filers
10k+
Activist 13D
0
Recent 13F institutional filers (SEC EDGAR full-text)
| Filer | Form | Filed |
|---|---|---|
| DSC Advisors, L.P. | 13F-HR | May 15, 2020 |
| HOMANS PETER | 13F-HR | Jan 15, 2003 |
| BRANT POINT INVESTMENT MANAGEMENT LLC | 13F-HR | Feb 13, 2025 |
| Delta Accumulation, LLC | 13F-HR | May 8, 2026 |
| DSC Advisors, L.P. | 13F-HR | Nov 14, 2017 |
Recent 8-K material events
| Date | Form | Description |
|---|---|---|
| Jun 18, 2026 | 8-K | 8-K |
| Apr 30, 2026 | 8-K | 8-K |
| Apr 28, 2026 | 8-K | 8-K |
| Apr 27, 2026 | 8-K | 8-K |
| Apr 24, 2026 | 8-K | 8-K |
| Feb 25, 2026 | 8-K | 8-K |
| Jan 27, 2026 | 8-K | 8-K |
| Oct 31, 2025 | 8-K | 8-K |
Free previewSEC Filing Analyst
SEC Filing Deep-Analysis
SEC Filing Analyst
score -50Deteriorating
64% conf
3 risk signal(s), 1 positive signal(s), 2 watch item(s) detected from XBRL filing diff analysis. 3 risk signal(s) detected versus 1 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
- NEW: Going concern doubt in latest filing: The term "going concern" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 2 filing(s).
- Material weakness in internal controls: The term "material weakness" appears in 19 recent filing(s) (vs 2 in the prior period). This risk language is ongoing.
- NEW: Restatement of financial statements in latest filing: The term "restate" "financial statements" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 7 filing(s).
- Operating cash flow exceeds net income: OCF is 1.80x net income, indicating high earnings quality — cash conversion is strong and accruals are not inflating reported profits.
- NEW: Impairment charge: Impairment charge appears in recent filings but not in the prior 24-month period. Monitor for materiality.
- NEW: Off-balance sheet arrangements: Off-balance sheet arrangements appears in recent filings but not in the prior 24-month period. Monitor for materiality.
- Endogenous analysis: 3 risk signal(s) detected versus 1 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
- 4 new risk-language term(s) detected in filing text: Going concern doubt, Restatement of financial statements, Impairment charge, Off-balance sheet arrangements.
- Ongoing high-severity risk language: Material weakness in internal controls.
Revenue
$64.97B
+7.9% YoY
Net income
$5.24B
-7.1% YoY
Operating cash flow
$9.43B
+10.7% YoY
Capex
$4.74B
+7.9% YoY
Total assets
$56.21B
+7.2% YoY
Total liabilities
$42.13B
+1.3% YoY
Long-term debt
$43.03B
+8.7% YoY
Cash & equivalents
$1.93B
+106.7% YoY
Filing quality score
65/100
stable
SEC XBRL metric changes (latest annual vs prior)
| Metric | Prior year | Latest year | Change | % Change |
|---|---|---|---|---|
| Revenue | $60.23B | $64.97B | $4.74B | +7.9% |
| Net income | $5.64B | $5.24B | $-401.0M | -7.1% |
| Operating cash flow | $8.52B | $9.43B | $909.0M | +10.7% |
| Capex | $4.39B | $4.74B | $349.0M | +7.9% |
| Total assets | $52.44B | $56.21B | $3.77B | +7.2% |
| Total liabilities | $41.59B | $42.13B | $537.0M | +1.3% |
| Long-term debt | $39.59B | $43.03B | $3.44B | +8.7% |
| Cash & equivalents | $935.0M | $1.93B | $998.0M | +106.7% |
| Stockholders equity | $-1.77B | $-2.50B | $-725.0M | -40.9% |
| Inventory | $2.02B | $1.74B | $-283.0M | -14.0% |
| Accounts receivable | $9.96B | $10.75B | $793.0M | +8.0% |
| Interest expense | $1.74B | $1.94B | $197.0M | +11.3% |
XBRL disclosure changes (new vs dropped concepts)
| Type | Concepts |
|---|---|
| Removed | AccrualForTaxesOtherThanIncomeTaxesCurrent, AccruedEmployeeBenefitsCurrent, AmortizationOfFinancingCosts, AmortizationOfIntangibleAssets, BuildingsAndImprovementsGross, ConstructionInProgressGross, CurrentFederalTaxExpenseBenefit, CurrentForeignTaxExpenseBenefit, CurrentStateAndLocalTaxExpenseBenefit, DeferredFederalIncomeTaxExpenseBenefit |
Risk language in filing text (EDGAR full-text search)
| Term | Severity | Recent | Prior | Status |
|---|---|---|---|---|
| Going concern doubt | high | 2 | 0 | NEW |
| Material weakness in internal controls | high | 19 | 2 | Ongoing |
| Restatement of financial statements | high | 7 | 0 | NEW |
| Impairment charge | medium | 30 | 0 | NEW |
| Restructuring | medium | 81 | 8 | Ongoing |
| Off-balance sheet arrangements | medium | 19 | 0 | NEW |
| Related party transactions | low | 25 | 2 | Ongoing |
Filing signal breakdown
Red flags: 3
Positive: 1
Watch: 2
Red flags
Positive
Watch
Unlock the rest
- ProValuationMarket cap $91.07B at $410.50 per share.
- ProPrice & TechnicalsPrice $410.50 — downtrend (below 200-DMA); 1-month momentum positive.
- ProMacro & RatesMarket regime: Risk-on · Supportive.
- ProRisk ScorecardComposite risk: Elevated.
This content is for Pro subscribers
Unlock the full breakdown from all analysts — valuation (DCF & Graham), price & technicals, macro, risk scorecard, and 13F/13D ownership flow — plus your research workspace.
3 sections free · 4 Pro sections locked · composite -14
Macro exposure
Defensive · Low sensitivityMacro regime: Risk-on · Supportive. HCA Healthcare is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.
Macro regime
Risk-on · Supportive
Yield curve
Normal
VIX
16.59
Fed funds
3.63%
CPI YoY
+4.2%
Analytical read
deterministic previewLatest annual report (10-K) filed Feb 10, 2026..
Risk
Elevated
Macro regime
Risk-on · Supportive
Macro exposure
Neutral
Descriptive analytics from public filings and macro data — not investment advice.
Peer comparison
Defensive groupHow HCA stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.
| Company | Score | Macro |
|---|---|---|
| Bristol-Myers Squibb BMY | 12 | Neutral |
| Cigna Group CI | 9 | Neutral |
| Procter & Gamble PG | 9 | Neutral |
| UnitedHealth Group UNH | 6 | Neutral |
| CVS Health Corp. CVS | 6 | Neutral |
| Zoetis Inc. ZTS | 3 | Neutral |
| Eli Lilly & Co. LLY | 3 | Neutral |
| Colgate-Palmolive CL | 1 | Neutral |
| Coca-Cola Co. KO | 1 | Neutral |
| Gilead Sciences GILD | 1 | Neutral |
| Intuitive Surgical Inc. ISRG | -1 | Neutral |
| Moderna Inc. MRNA | -4 | Neutral |
| Regeneron Pharmaceuticals REGN | -4 | Neutral |
| DexCom Inc. DXCM | -7 | Neutral |
| AbbVie Inc. ABBV | -7 | Neutral |
| Johnson & Johnson JNJ | -7 | Neutral |
| Vertex Pharmaceuticals VRTX | -8 | Neutral |
| Kimberly-Clark Corp. KMB | -10 | Neutral |
| Sysco Corp. SYY | -10 | Neutral |
| Danaher Corp. DHR | -11 | Neutral |
| Mondelez International MDLZ | -11 | Neutral |
| Merck & Co. MRK | -11 | Neutral |
| Biogen Inc. BIIB | -11 | Neutral |
| Amgen Inc. AMGN | -14 | Neutral |
| HCA Healthcare HCA● you | -14 | Neutral |
| Illumina Inc. ILMN | -16 | Neutral |
| Kroger Co. KR | -16 | Neutral |
| Thermo Fisher Scientific TMO | -18 | Neutral |
| Costco Wholesale COST | -18 | Neutral |
| PepsiCo Inc. PEP | -21 | Neutral |
| Walmart Inc. WMT | -25 | Neutral |
| Hershey Co. HSY | -26 | Neutral |
| Abbott Laboratories ABT | -30 | Neutral |
| Pfizer Inc. PFE | -49 | Neutral |